Skip to main content

SpaceLiinTech

Category: AI in Healthcare

South Korea’s pioneering space biopharma startup providing an integrated platform for drug discovery, protein crystallization, and pharmaceutical manufacturing in microgravity environments. SpaceLiinTech was founded in 2021. The company is led by Hak Soon Yoon. Based in Daejeon, South Korea. Team size: 10-50. Total funding raised: $7.0M. Latest round: Series B. Key investors include Woori Venture Partners, Company K Partners, Sunbo Angel Partners, Industrial Bank of Korea (IBK), KDB Bank.

Founded
2021
Headquarters
Daejeon, South Korea
Team size
10-50
Total funding
$7.0M

Value proposition

Leverages the unique microgravity environment of space to produce high-purity protein crystals and biological materials impossible to create on Earth, significantly improving drug efficacy and reducing research costs through fully automated space modules.

Products and solutions

BEE-PC1: A fully automated, astronaut-independent protein crystallization research module successfully tested on the International Space Station (ISS)., BEE-1000: A specialized space-bio research satellite platform for long-term drug discovery and manufacturing in Low Earth Orbit (LEO)., Space CDMO/CRO Platform: Integrated contract development and manufacturing services for space-based biopharmaceuticals., AI Space Payload: High-performance, low-power NPU-based hardware (developed with Mobilint) for real-time On-device AI analysis of space experiments.

Unique value

As Korea's first space medicine startup, they eliminate the high cost of human intervention in space by utilizing 'BEE' (Biomedical Extra-Terrestrial Enclosure) modules that automate complex biological experiments.

Target customer

Global pharmaceutical companies, biotechnology firms, research institutions (KIST, Harvard Medical School), and government aerospace agencies.

Industries served

Space Technology, Biotechnology & Pharmaceuticals, Healthcare AI, Deep Tech

Technology advantage

Maintains a full-cycle research pipeline from ground-based microgravity simulation (drop towers) to ISS and satellite-based manufacturing; further enhanced by proprietary high-performance AI hardware for autonomous mission control and data processing.

How they differentiate

Integrates high-performance NPU-based AI hardware for real-time on-orbit data processing; operates the world's first private-sector 'Drop Tower' for ground-based microgravity validation; focuses on astronaut-independent, fully automated 'BEE' (Biomedical Extra-Terrestrial Enclosure) modules.

Main competitors

Varda Space Industries, SpacePharma, Yuri, Space Forge

Key partnerships

Mobilint: Co-development of AI-driven space hardware and NPUs., Voyager Space: Strategic partnership for ISS platform access and infrastructure., Harvard Medical School & KIST: Joint research for space-based drug delivery and lung cancer treatment data analysis., Innospace & Intergravity Technologies: Alliance for space medicine launch services and microgravity research infrastructure., Aptis (Dong-A ST): Collaboration for cancer drug discovery using microgravity platforms.

Notable customers

NASA Langley Research Center, Mobilint, Dong-A ST (Aptis), Voyager Space, Harvard Medical School, KIST

Major milestones

Selection for the South Korean government's 'Super Gap Startup 1000+' project (2024), Completion of Series A funding led by Woori Venture Partners (April 2024), Launch and successful mission of BEE-PC1 drug discovery module on the International Space Station (Sept 2025), Establishment of a strategic AI solution partnership with Mobilint (Feb 2026)

Growth metrics

Successfully transitioned from ground-based R&D to active ISS missions (BEE-PC1) and AI-driven space hardware development (Mobilint partnership).

Market positioning

Pioneering South Korean space biopharma platform provider bridging terrestrial drug validation and in-orbit manufacturing.

Geographic focus

South Korea, North America (NASA/ISS), and Global Space Platforms (LEO satellites)

Patents and IP

Holds proprietary IP for automated protein crystallization systems and space-grade modular experiment enclosures (BEE series); lead developer for the Korean government's project on 'Innovative Space Medicine Medical Technology.'

About Hak Soon Yoon

Hak Soon Yoon (Hargsoon Yoon) is a Professor of Neural Engineering at Norfolk State University (USA) and served as a Guest Professor at Harvard Medical School (2022-2023). He holds a Ph.D. in Physics from Pennsylvania State University and has collaborated extensively with NASA (Langley Research Center). He founded Liin Technologies in the US (2017) and SpaceLiinTech in South Korea (2021) to pioneer the space medicine industry.

Official website: